Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL

ClinicalTrials.gov ID: NCT02811783

Public ClinicalTrials.gov record NCT02811783. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This multi-center, double-blind, vehicle-controlled, randomized crossover design study will evaluate the safety and efficacy of topically applied naloxone lotion, 0.5%, for the treatment of pruritus in patients with the mycosis fungoides (MF) or Sézary syndrome (SS) Forms of Cutaneous T-cell Lymphoma (CTCL). This study will also determine if there is systemic absorption of the drug in a subset of subjects and if so, describe the range and mean plasma levels reached after two weeks of three time daily (TID) dosing. Funding Source - FDA OOPD

Study identification

NCT ID
NCT02811783
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Elorac, Inc.
Industry
Enrollment
59 participants

Conditions and interventions

Eligibility (public fields only)

Age range
21 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 2017 (Actual)
Primary completion
Sep 2022 (Actual)
Completion
Sep 2022 (Actual)
Last update posted
Oct 28, 2022

2017 – 2022

United States locations

U.S. sites
16
U.S. states
12
U.S. cities
14
Facility City State ZIP Site status
University of Arkansas for Medical Sciences Little Rock Arkansas 72205 —
City of Hope Duarte California 91010 —
Stanford University Palo Alto California 94304 —
USSF Health Morsani Center for Advanced Healthcare Tampa Florida 33612 —
Cleveland Clinic Indian River Hospital Vero Beach Florida 32960 —
Robert H. Lurie Comprehensive Cancer Center Chicago Illinois 60611 —
Rush University Medical Center Chicago Illinois 60612 —
Dawes Fretzin Clinical Research Group, LLC Indianapolis Indiana 46250 —
University of Minnesota Minneapolis Minnesota 55455 —
St. Louis University Dermatology St Louis Missouri 63104 —
Washington University School of Medicine St. Louis St Louis Missouri 63110 —
Stony Brook Dermatology Stony Brook New York 11790 —
University Hospitals Cleveland Medical Center Cleveland Ohio 44106 —
University of Texas MD Anderson Cancer Center Houston Texas 77030 —
Inova Schar Cancer Institute Fairfax Virginia 22031 —
University of Washington / Seattle Cancer Care Alliance (SCCA) Seattle Washington 98109 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02811783, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 28, 2022 · Synced Oct 30, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02811783 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →